Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Julius Clinical | INDUSTRY |
| Stichting TRICALS Foundation | OTHER |
Not provided
Not provided
Not provided
Not provided
Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| FAB122 | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| FAB122 | Drug | Daily dose 100 mg |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Score After 48 Weeks. | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. | 48 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Combined Assessment of Function and Survival (CAFS) at 48 and 72 Weeks. | The CAFS (Combined assessment of function and survival) combined information on survival time and ALSFRS-R (ALS Functional Rating Scale-Revised) scores. For this endpoint, each subject's outcome was ranked: the worst subject outcomes received the lowest rank numbers such that a higher CAFS score indicates a better outcome. CAFS rankings are computed using: Survival data: Patients who die earlier are ranked lower than those who survive longer. ALSFRS-R scores: For patients with the same survival duration, ranks are determined by their functional decline (change in ALSFRS-R from baseline). For this study the range could go from 1 to 302. Better Outcome: Higher CAFS rank, indicating prolonged survival and/or less functional decline. Worse Outcome: Lower CAFS rank, indicating shorter survival and/or greater functional decline. |
Not provided
Main Inclusion Criteria:
Age 18 - 80 years (both inclusive), male or female;
Diagnosis of definite, probable, probable laboratory supported or possible ALS as based on the El Escorial and the revised Airlie House diagnostic criteria for ALS;
Onset of first symptoms* no longer than 24 months prior to randomization;
*Date of onset is the date the patient reported one or more of the following symptoms:
Muscle weakness in limbs
Speech/swallowing difficulties
Respiratory symptoms: dyspnea was noticed
SVC equal to or more than 70% of the predicted normal value for gender, height and age at screening visit;
Change in ALSFRS-R score between 0.35 points and 1.5 points per month (both inclusive) in the period from onset of first symptoms to the Screening visit;
Capable of providing informed consent and complying with trial procedures.
Main Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospitals Leuven | Leuven | Belgium | ||||
| CHRU de Lille - Hôpital Roger Salengro |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41137739 | Derived | van Wijk IF, Kraneburg L, van Eijk RPA, Veldink JH, van Es MA, Westeneng HJ, van den Berg LH. Prodromal symptoms in amyotrophic lateral sclerosis from the perspective of the patient and of the caregiver. Amyotroph Lateral Scler Frontotemporal Degener. 2026 May;27(3-4):263-273. doi: 10.1080/21678421.2025.2574687. Epub 2025 Oct 25. |
Not provided
Not provided
Not provided
From the 313 randomized participants, 9 patients were excluded from the analysis and 2 were randomized by mistake and not treated. So a total of 302 participants are considered in the analysis.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | FAB122 | FAB122: Daily dose 100 mg |
| FG001 | Placebo | Placebo: Daily dose |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | May 24, 2023 | Sep 26, 2024 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Daily dose |
|
| 48 weeks and 72 weeks |
| Survival Probability | Results are based on the overall survival over 72 weeks of treatment, the result is the survival probability estimated over 72 weeks. Survival probability is calculated considering time to death, tracheostomy or initiation of non-invasive ventilation for more than 20 hours a day for more than 10 consecutive days, over 72 weeks. | 72 weeks |
| Change From Baseline in ALSFRS-R Score After 24 and 72* Weeks | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. | 24 weeks, 72 weeks |
| The Slope of the Decrease in ALSFRS-R Score Over Time at 24, 48 and 72* Weeks; | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. For this outcome, measures on the ALSFRS-R were used to determine the slope of the decrease. | 24, 48, 72 weeks |
| Change From Baseline in ALSFRS-R Score on Bulbar Function (Question 1-3 of the ALSFRS-R) After 24, 48 and 72* Weeks; | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. In this outcome, the Bulbar function (as part of ALSFRS-R) is evaluated, it is related to Speech, Salivation and Swallowing. The maximum score on Bulbar function is 12, and the minimum is 0. Higher score better outcome. | 24, 48 and 72 weeks |
| Change From Baseline ALS Functional Rating Scale - Revised Score - Fine Motor Function | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. In this outcome, the fine motor function (as part of ALSFRS-R) is evaluated, it is related to Handwriting, Eating and Cutting food, Dressing and hygiene. The maximum score on fine motor function is 12, and the minimum is 0. Higher score better outcome. | 24, 48 and 72 weeks |
| Change From Baseline ALS Functional Rating Scale - Revised Score - Gross Motor Function | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. In this outcome, the gross motor function (as part of ALSFRS-R) is evaluated, it is related to Climbing stairs, Walking, Rising from a chair. The maximum score on gross motor function is 12, and the minimum is 0. Higher score better outcome. | 24, 48, 72 weeks |
| Change From Baseline ALS Functional Rating Scale - Revised Score - Respiratory Function | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. In this outcome, the respiratory function (as part of ALSFRS-R) is evaluated, it is related to Dyspnea, Orthopnea, Breathing insufficiency. The maximum score on respiratory function is 12, and the minimum is 0. Higher score better outcome. | 24, 48, 72 weeks |
| Time to a 3, 6, 9 and 12 Points Change or Death From Baseline in ALSFRS-R Score Over 72* Weeks; | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. For this outcome, the time a 3, 6, 9 and 12 points change or death from baseline in ALSFRS-R. | 72 weeks (+/-1 week visit window) |
| Change in Clinical Staging (King's Staging System and MiToS) Over 72 Weeks | The King's staging system is a simple clinical staging system, which defines 4 stages of ALS. The 1st 3 stages are defined by functional involvement of a region: bulbar, upper limbs, and lower limbs. The number of regions involved gives the stage. Stage 4 is reached if swallowing (4A) or respiratory (4B) difficulty is severe enough to require intervention. The outcome of this measure shows the number of patients which staging decline of 1 point or more or No decline. | 72 weeks |
| Overall Survival: Proportion of Subjects Alive (Survival Rate) After 24, 48 and 72* Weeks; | 24, 48 and 72* weeks; |
| Proportion of Subjects Alive and no Tracheostomy, or no Initiation of Non-invasive Ventilation for More Than 20 Hours a Day for More Than 10 Consecutive Days After 24, 48 and 72* Weeks | 24, 48 and 72* weeks |
| Change From Baseline in Slow Vital Capacity (SVC, Liters) at 24, 48 and 72* Weeks; | 24, 48 and 72* weeks |
| Change From Baseline in the Overall Mega Score for the Hand-held Dynamometer (HHD) at 24, 48 and 72* Weeks. | HHD is a procedure for quantitative strength testing performed in the upper and lower extremities bilaterally. The overall mega score are derived as z-scores of average muscle HHD assessments, percent changes from Baseline are used to derive individual muscle scores. Muscle strength is expressed as the percent change from baseline: (post-baselinevalue-baselinevalue)/baselinevalue×100(post-baseline value - baseline value) / baseline value \times 100(post-baselinevalue-baselinevalue)/baselinevalue×100. If the baseline value is zero, the data is considered missing. The HDD mega-score averages strength across four muscle locations. It is calculated by averaging the non-missing transformed values. Maximum muscle strength is then standardized using a z-score, based on data from a healthy population. Z-score of 0 represents the healthy population mean. Negative z-score value means worse outcome. | 24, 48 and 72* weeks |
| Change From Baseline in the Total Score on the ALS Assessment Questionnaire-40-Item (ALSAQ-40) Form at 24, 48 and 72* Weeks; | ALS Assessment Questionnaire-40-Item. The ALSAQ-40 is specifically used to measure the subjective wellbeing of patients with ALS. There are 40 items/questions in the long form, the ALSAQ-40, with 5 discrete scales: physical mobility (10 items), activities of daily living and independence (10 items), eating and drinking (3 items), communication (7 items), and emotional reactions (10 items). Range is from 0 to 100 scale, where 0 indicates the best quality of life and 100 the worst. | 24, 48 and 72* weeks |
| Change From Baseline in EuroQoL - 5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire Score 24, 48 and 72* Weeks. | European Quality of Life 5 levels and 5 dimensions is a generic questionnaire of health-related quality of life. 5 Domains: Mobility, Self-care, Usual activities, Pain/Discomfort and Anxiety/Depression. Scale range is from 0 to 100, being 0 the worst and 100 the best. | 24, 48 and 72* weeks |
| Change From Baseline in Visual Analogue Scale (VAS) Score at 24, 48 and 72* Weeks. | The Health-Related Quality of Life (HR-QoL) is a questionnaire using a Visual Analog Scale (VAS) ranging from 0 (bad) to 100 (very good). | 24, 48 and 72* weeks |
| Proportion of Subjects With a Change of ≥8, ≥4, and ≥9 for ALS Specific, ALS Non-Specific, and ECAS (Edinburgh Cognitive and Behavioural ALS Screen) Total Score; | The ECAS (Edinburgh Cognitive and behavioural ALS Screen) is a brief multidomain assessment originally designed for people with ALS. Total Score Range: 0 to 136 points. Higher scores indicate better cognitive function. For ALS-Specific (Assesses cognitive domains most often affected in ALS) Score Range: 0 to 100 points. Higher scores indicate better cognitive function. And ALS Non-Specific (Evaluates broader cognitive abilities unrelated to ALS pathology) Score Range: 0 to 36 points. Higher scores indicate better cognitive function. | 72 weeks |
| Lille |
| France |
| CHU de Limoges - Hôpital Dupuytren | Limoges | France |
| Centre Hospitalo-Universitaire La Timone | Marseille | France |
| CHU de Montpellier | Montpellier | France |
| CHU Nice | Nice | France |
| Hôpital de la Salpêtrière | Paris | France |
| CHRU de Tours | Tours | France |
| Universitätsmedizin Berlin | Berlin | Germany |
| Universitätsklinikum Carl Gustav Carus | Dresden | Germany |
| Hannover Medical School | Hanover | Germany |
| Universitätsklinikum Ulm | Ulm | Germany |
| Trinity College Dublin/Beaumont Hospital | Dublin | Ireland |
| Azienda Ospedaliera Universitaria Cagliari | Cagliari | Italy |
| Centro Clinico NEMO | Milan | Italy |
| University of Milan Medical School | Milan | Italy |
| University of Torino - Rita Levi Montalcini Department of Neuroscience | Milan | Italy |
| Azienda Ospedaliero Universitaria Di Modena | Modena | Italy |
| Azienda Ospedaliera Universitaria ( A O U ) dell'Università degli studi della Campania "Luigi Vanvitelli" | Naples | Italy |
| University of Padua - Azienda Ospedaliera di Padova | Padua | Italy |
| UMC Utrecht | Utrecht | Netherlands |
| Centrum Medyczne Neuromed | Bydgoszcz | Poland |
| Linden Medical Centre | Krakow | Poland |
| City Clinic SP. z o. o. | Warsaw | Poland |
| Centro Hospitalar Universitário Lisboa-Norte | Lisbon | Portugal |
| Hospital Universitari de Bellvitge | Barcelona | Spain |
| Hospital Universitario de Basurto | Bilbao | Spain |
| Hospital San Rafael | Madrid | Spain |
| Hospital Universitario La Paz-Carlos III | Madrid | Spain |
| Hospital Regional Universitario Málaga | Málaga | Spain |
| Hospital Clínico Universitario de Santiago de Compostela | Santiago de Compostela | Spain |
| Hospital Virgen del Rocio | Seville | Spain |
| Hospital Universitario y Politécnico La Fe | Valencia | Spain |
| Karolinska Institutet | Stockholm | Sweden |
| King's College London | London | United Kingdom |
| Manchester MND care centre | Manchester | United Kingdom |
| John Radcliffe Hospital | Oxford | United Kingdom |
| Sheffield Teaching Hospitals NHS Foundation Trust | Sheffield | United Kingdom |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | FAB122 | FAB122: Daily dose 100 mg |
| BG001 | Placebo | Placebo: Daily dose |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Score After 48 Weeks. | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. | Posted | Mean | Standard Deviation | units on a scale | 48 weeks |
|
|
| |||||||||||||||||||||||||||||
| Secondary | Combined Assessment of Function and Survival (CAFS) at 48 and 72 Weeks. | The CAFS (Combined assessment of function and survival) combined information on survival time and ALSFRS-R (ALS Functional Rating Scale-Revised) scores. For this endpoint, each subject's outcome was ranked: the worst subject outcomes received the lowest rank numbers such that a higher CAFS score indicates a better outcome. CAFS rankings are computed using: Survival data: Patients who die earlier are ranked lower than those who survive longer. ALSFRS-R scores: For patients with the same survival duration, ranks are determined by their functional decline (change in ALSFRS-R from baseline). For this study the range could go from 1 to 302. Better Outcome: Higher CAFS rank, indicating prolonged survival and/or less functional decline. Worse Outcome: Lower CAFS rank, indicating shorter survival and/or greater functional decline. | Posted | Mean | Standard Deviation | score on a scale | 48 weeks and 72 weeks |
| |||||||||||||||||||||||||||||||
| Secondary | Survival Probability | Results are based on the overall survival over 72 weeks of treatment, the result is the survival probability estimated over 72 weeks. Survival probability is calculated considering time to death, tracheostomy or initiation of non-invasive ventilation for more than 20 hours a day for more than 10 consecutive days, over 72 weeks. | Posted | Number | 95% Confidence Interval | Survival probability | 72 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in ALSFRS-R Score After 24 and 72* Weeks | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. | Posted | Mean | Standard Deviation | units on a scale | 24 weeks, 72 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | The Slope of the Decrease in ALSFRS-R Score Over Time at 24, 48 and 72* Weeks; | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. For this outcome, measures on the ALSFRS-R were used to determine the slope of the decrease. | Posted | Mean | Standard Error | units on a scale/week | 24, 48, 72 weeks |
| |||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in ALSFRS-R Score on Bulbar Function (Question 1-3 of the ALSFRS-R) After 24, 48 and 72* Weeks; | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. In this outcome, the Bulbar function (as part of ALSFRS-R) is evaluated, it is related to Speech, Salivation and Swallowing. The maximum score on Bulbar function is 12, and the minimum is 0. Higher score better outcome. | Posted | Mean | Standard Deviation | units on a scale | 24, 48 and 72 weeks |
| |||||||||||||||||||||||||||||||
| Secondary | Change From Baseline ALS Functional Rating Scale - Revised Score - Fine Motor Function | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. In this outcome, the fine motor function (as part of ALSFRS-R) is evaluated, it is related to Handwriting, Eating and Cutting food, Dressing and hygiene. The maximum score on fine motor function is 12, and the minimum is 0. Higher score better outcome. | Posted | Mean | Standard Deviation | units on a scale | 24, 48 and 72 weeks |
| |||||||||||||||||||||||||||||||
| Secondary | Change From Baseline ALS Functional Rating Scale - Revised Score - Gross Motor Function | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. In this outcome, the gross motor function (as part of ALSFRS-R) is evaluated, it is related to Climbing stairs, Walking, Rising from a chair. The maximum score on gross motor function is 12, and the minimum is 0. Higher score better outcome. | Posted | Mean | Standard Deviation | units on a scale | 24, 48, 72 weeks |
| |||||||||||||||||||||||||||||||
| Secondary | Change From Baseline ALS Functional Rating Scale - Revised Score - Respiratory Function | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. In this outcome, the respiratory function (as part of ALSFRS-R) is evaluated, it is related to Dyspnea, Orthopnea, Breathing insufficiency. The maximum score on respiratory function is 12, and the minimum is 0. Higher score better outcome. | Posted | Mean | Standard Deviation | units on a scale | 24, 48, 72 weeks |
| |||||||||||||||||||||||||||||||
| Secondary | Time to a 3, 6, 9 and 12 Points Change or Death From Baseline in ALSFRS-R Score Over 72* Weeks; | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome. For this outcome, the time a 3, 6, 9 and 12 points change or death from baseline in ALSFRS-R. | The first 100 patients in the study were planned to complete a 72 weeks follow up. This analysis is done over this population. | Posted | Median | Inter-Quartile Range | days | 72 weeks (+/-1 week visit window) |
|
| |||||||||||||||||||||||||||||
| Secondary | Change in Clinical Staging (King's Staging System and MiToS) Over 72 Weeks | The King's staging system is a simple clinical staging system, which defines 4 stages of ALS. The 1st 3 stages are defined by functional involvement of a region: bulbar, upper limbs, and lower limbs. The number of regions involved gives the stage. Stage 4 is reached if swallowing (4A) or respiratory (4B) difficulty is severe enough to require intervention. The outcome of this measure shows the number of patients which staging decline of 1 point or more or No decline. | Posted | Count of Participants | Participants | No | 72 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Overall Survival: Proportion of Subjects Alive (Survival Rate) After 24, 48 and 72* Weeks; | Posted | Number | 95% Confidence Interval | proportion of participants | 24, 48 and 72* weeks; |
| ||||||||||||||||||||||||||||||||
| Secondary | Proportion of Subjects Alive and no Tracheostomy, or no Initiation of Non-invasive Ventilation for More Than 20 Hours a Day for More Than 10 Consecutive Days After 24, 48 and 72* Weeks | Posted | Number | 95% Confidence Interval | proportion of participants | 24, 48 and 72* weeks |
| ||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Slow Vital Capacity (SVC, Liters) at 24, 48 and 72* Weeks; | Posted | Mean | Standard Deviation | liters | 24, 48 and 72* weeks |
| ||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the Overall Mega Score for the Hand-held Dynamometer (HHD) at 24, 48 and 72* Weeks. | HHD is a procedure for quantitative strength testing performed in the upper and lower extremities bilaterally. The overall mega score are derived as z-scores of average muscle HHD assessments, percent changes from Baseline are used to derive individual muscle scores. Muscle strength is expressed as the percent change from baseline: (post-baselinevalue-baselinevalue)/baselinevalue×100(post-baseline value - baseline value) / baseline value \times 100(post-baselinevalue-baselinevalue)/baselinevalue×100. If the baseline value is zero, the data is considered missing. The HDD mega-score averages strength across four muscle locations. It is calculated by averaging the non-missing transformed values. Maximum muscle strength is then standardized using a z-score, based on data from a healthy population. Z-score of 0 represents the healthy population mean. Negative z-score value means worse outcome. | Posted | Mean | Standard Deviation | Z-Score | 24, 48 and 72* weeks |
| |||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the Total Score on the ALS Assessment Questionnaire-40-Item (ALSAQ-40) Form at 24, 48 and 72* Weeks; | ALS Assessment Questionnaire-40-Item. The ALSAQ-40 is specifically used to measure the subjective wellbeing of patients with ALS. There are 40 items/questions in the long form, the ALSAQ-40, with 5 discrete scales: physical mobility (10 items), activities of daily living and independence (10 items), eating and drinking (3 items), communication (7 items), and emotional reactions (10 items). Range is from 0 to 100 scale, where 0 indicates the best quality of life and 100 the worst. | Posted | Mean | Standard Deviation | units on a scale | 24, 48 and 72* weeks |
| |||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in EuroQoL - 5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire Score 24, 48 and 72* Weeks. | European Quality of Life 5 levels and 5 dimensions is a generic questionnaire of health-related quality of life. 5 Domains: Mobility, Self-care, Usual activities, Pain/Discomfort and Anxiety/Depression. Scale range is from 0 to 100, being 0 the worst and 100 the best. | Posted | Mean | Standard Deviation | units on a scale | 24, 48 and 72* weeks |
| |||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Visual Analogue Scale (VAS) Score at 24, 48 and 72* Weeks. | The Health-Related Quality of Life (HR-QoL) is a questionnaire using a Visual Analog Scale (VAS) ranging from 0 (bad) to 100 (very good). | Posted | Mean | Standard Deviation | units on a scale | 24, 48 and 72* weeks |
| |||||||||||||||||||||||||||||||
| Secondary | Proportion of Subjects With a Change of ≥8, ≥4, and ≥9 for ALS Specific, ALS Non-Specific, and ECAS (Edinburgh Cognitive and Behavioural ALS Screen) Total Score; | The ECAS (Edinburgh Cognitive and behavioural ALS Screen) is a brief multidomain assessment originally designed for people with ALS. Total Score Range: 0 to 136 points. Higher scores indicate better cognitive function. For ALS-Specific (Assesses cognitive domains most often affected in ALS) Score Range: 0 to 100 points. Higher scores indicate better cognitive function. And ALS Non-Specific (Evaluates broader cognitive abilities unrelated to ALS pathology) Score Range: 0 to 36 points. Higher scores indicate better cognitive function. | Posted | Count of Participants | Participants | 72 weeks |
|
72 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | FAB122 | FAB122: Daily dose 100 mg | 20 | 205 | 62 | 205 | 180 | 205 |
| EG001 | Placebo | Placebo: Daily dose | 7 | 97 | 28 | 97 | 82 | 97 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Respiratory disorder | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Pneumonia | Infections and infestations | Systematic Assessment |
| ||
| COVID-19 | Infections and infestations | Systematic Assessment |
| ||
| Fall | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Cardiac arrest | Cardiac disorders | Systematic Assessment |
| ||
| Myocardial infarction | Cardiac disorders | Systematic Assessment |
| ||
| Dysphagia | Gastrointestinal disorders | Systematic Assessment |
| ||
| Death | General disorders | Systematic Assessment |
| ||
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Lung disorder | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Pneumonia aspiration | Infections and infestations | Systematic Assessment |
| ||
| Lower respiratory tract infection | Infections and infestations | Systematic Assessment |
| ||
| Urinary tract infection | Infections and infestations | Systematic Assessment |
| ||
| Bronchitis | Infections and infestations | Systematic Assessment |
| ||
| Post procedural infection | Infections and infestations | Systematic Assessment |
| ||
| Septic shock | Infections and infestations | Systematic Assessment |
| ||
| Urosepsis | Infections and infestations | Systematic Assessment |
| ||
| Respiratory tract infection | Infections and infestations | Systematic Assessment |
| ||
| Femural neck fracture | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Femur fracture | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Concussion | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Fibula fracture | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Head injury | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Joint dislocation | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Humerus fracture | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Rib fracture | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Subdural haematoma | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Acute coronary syndrome | Cardiac disorders | Systematic Assessment |
| ||
| Cardiac failure | Cardiac disorders | Systematic Assessment |
| ||
| Myocardial ischaemia | Cardiac disorders | Systematic Assessment |
| ||
| Acute myocardial infarction | Cardiac disorders | Systematic Assessment |
| ||
| Intestinal haemorrhage | Gastrointestinal disorders | Systematic Assessment |
| ||
| Intestinal obstruction | Gastrointestinal disorders | Systematic Assessment |
| ||
| Nausea | Gastrointestinal disorders | Systematic Assessment |
| ||
| Vomiting | Gastrointestinal disorders | Systematic Assessment |
| ||
| Pyrexia | General disorders | Systematic Assessment |
| ||
| Brain death | General disorders | Systematic Assessment |
| ||
| Cerebral haematoma | Nervous system disorders | Systematic Assessment |
| ||
| Cerebral haemorrhage | Nervous system disorders | Systematic Assessment |
| ||
| Hypoxic ischaemic encephalopathy | Nervous system disorders | Systematic Assessment |
| ||
| Weight decrease | Investigations | Systematic Assessment |
| ||
| Oxygen saturation decreased | Investigations | Systematic Assessment |
| ||
| Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
| ||
| Thyroid cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
| ||
| Acute psychosis | Psychiatric disorders | Systematic Assessment |
| ||
| Panic attack | Psychiatric disorders | Systematic Assessment |
| ||
| Hypertensive crisis | Vascular disorders | Systematic Assessment |
| ||
| Deep vein thrombosis | Vascular disorders | Systematic Assessment |
| ||
| Cholecystitis | Hepatobiliary disorders | Systematic Assessment |
| ||
| Cholelithasis | Hepatobiliary disorders | Systematic Assessment |
| ||
| Dehydration | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Utherine haemorrhage | Reproductive system and breast disorders | Systematic Assessment |
| ||
| Hospitalisation | Surgical and medical procedures | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| COVID-19 | Infections and infestations | Systematic Assessment |
| ||
| Nasopharygitis | Infections and infestations | Systematic Assessment |
| ||
| Urinary tract infection | Infections and infestations | Systematic Assessment |
| ||
| Upper respiratory tract infection | Infections and infestations | Systematic Assessment |
| ||
| Constipation | Gastrointestinal disorders | Systematic Assessment |
| ||
| Dysphagia | Gastrointestinal disorders | Systematic Assessment |
| ||
| Fall | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Nerve conduction studies abnormal | Investigations | Systematic Assessment |
| ||
| Arthralgia | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Back pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Headache | Nervous system disorders | Systematic Assessment |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Clinical Operations Head | Ferrer | +34 649 442 389 | nalbareda@ferrer.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Dec 7, 2023 | Oct 31, 2024 | SAP_001.pdf |
| ID | Term |
|---|---|
| D000690 | Amyotrophic Lateral Sclerosis |
| ID | Term |
|---|---|
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D016472 | Motor Neuron Disease |
| D019636 | Neurodegenerative Diseases |
| D057177 | TDP-43 Proteinopathies |
| D009468 | Neuromuscular Diseases |
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Placebo 48 Weeks |
Placebo: Daily dose |
|
|
|
|
| OG005 | Placebo 72 Weeks | Placebo: Daily dose |
|
|
FAB122: Daily dose 100 mg |
| OG005 | Placebo 72 Weeks | Placebo: Daily dose |
|
|
FAB122: Daily dose 100 mg |
| OG005 | Placebo 72 Weeks | Placebo: Daily dose |
|
|
FAB122: Daily dose 100 mg |
| OG005 | Placebo 72 Weeks | Placebo: Daily dose |
|
|
FAB122: Daily dose 100 mg |
| OG005 | Placebo 72 Weeks | Placebo: Daily dose |
|
|
|
|
|
|
Placebo: Daily dose
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| OG003 | Placebo 48 Weeks | Placebo: Daily dose |
| OG004 | FAB122 100mg 72 Weeks | FAB122: Daily dose 100 mg |
| OG005 | Placebo 72 Weeks | Placebo: Daily dose |
|
|
| OG004 |
| FAB122 100mg 72 Weeks |
FAB122: Daily dose 100 mg |
| OG005 | Placebo 72 Weeks | Placebo: Daily dose |
|
|
| OG005 | Placebo 72 Weeks | Placebo: Daily dose |
|
|
Placebo: Daily dose |
|
|
| OG004 | FAB122 100mg 72 Weeks | FAB122: Daily dose 100 mg |
| OG005 | Placebo 72 Weeks | Placebo: Daily dose |
|
|